Novel Ghrelin Analogs: Longer-Acting and More Selective Versions for Clinical Use
Novel ghrelin analogs with improved stability, selectivity, and duration of action were developed and characterized, advancing ghrelin-based drug development for GH deficiency, appetite disorders, and cardiovascular protection.
Quick Facts
What This Study Found
Multiple novel ghrelin analogs were designed with improved pharmacokinetic properties (longer half-life, better stability) and selectivity profiles compared to native ghrelin, maintaining GH-releasing and appetite effects in animal models.
Key Numbers
How They Did This
animal-study study examining ghrp and peptide-design.
Why This Research Matters
Advances understanding of ghrp, peptide-design, bioavailability with translational implications.
The Bigger Picture
Contributes to the growing body of peptide research with implications for clinical development and therapeutic applications.
What This Study Doesn't Tell Us
Study-specific limitations apply; see abstract for details.
Questions This Raises
- ?Further research needed to confirm and extend these findings.
- ?Clinical translation and safety need evaluation.
- ?Optimal dosing and delivery require characterization.
Trust & Context
- Key Stat:
- Key finding Multiple novel ghrelin analogs were designed with improved pharmacokinetic properties (longer half-life, better stability) and selectivity profiles co
- Evidence Grade:
- preliminary evidence from animal-study study design.
- Study Age:
- Published in 2004.
- Original Title:
- Novel analogs of ghrelin: physiological and clinical implications.
- Published In:
- European journal of endocrinology, 151 Suppl 1, S71-5 (2004)
- Authors:
- Halem, Heather A(3), Taylor, John E(4), Dong, Jesse Z(3), Shen, Yeelana, Datta, Rakesh, Abizaid, Alfonso, Diano, Sabrina, Horvath, Tamas, Zizzari, Philippe, Bluet-Pajot, Marie-Thèrèse, Epelbaum, Jacques, Culler, Michael D
- Database ID:
- RPEP-00920
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was the main focus of this study?
Novel Ghrelin Analogs: Longer-Acting and More Selective Versions for Clinical Use
What was discovered?
Novel ghrelin analogs with improved stability, selectivity, and duration of action were developed and characterized, advancing ghrelin-based drug development for GH deficiency, appetite disorders, and cardiovascular protection.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00920APA
Halem, Heather A; Taylor, John E; Dong, Jesse Z; Shen, Yeelana; Datta, Rakesh; Abizaid, Alfonso; Diano, Sabrina; Horvath, Tamas; Zizzari, Philippe; Bluet-Pajot, Marie-Thèrèse; Epelbaum, Jacques; Culler, Michael D. (2004). Novel analogs of ghrelin: physiological and clinical implications.. European journal of endocrinology, 151 Suppl 1, S71-5.
MLA
Halem, Heather A, et al. "Novel analogs of ghrelin: physiological and clinical implications.." European journal of endocrinology, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Novel analogs of ghrelin: physiological and clinical implica..." RPEP-00920. Retrieved from https://rethinkpeptides.com/research/halem-2004-novel-analogs-of-ghrelin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.